 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

---
- Zacks Investment Research downgraded shares of Travere Therapeutics (NASDAQ:TVTX)
  from a buy rating to a hold rating in a research note released on Tuesday , Zacks.com
  reports. According to Zacks, Travere Therapeutics Inc. is a biopharmaceutical company.
  It engages to identify, develop and ...


Zacks Investment Research Lowers Travere Therapeutics (NASDAQ:TVTX) to Hold

---
- Travere Therapeutics (NASDAQ:TVTX) was upgraded by Zacks Investment Research from
  a sell rating to a hold rating in a report released on Wednesday, Zacks.com reports.
  According to Zacks, Travere Therapeutics Inc. is a biopharmaceutical company. It
  engages to ...


Travere Therapeutics (NASDAQ:TVTX) Rating Increased to Hold at Zacks Investment Research

---
- Zacks Investment Research lowered shares of Travere Therapeutics (NASDAQ:TVTX) from
  a hold rating to a sell rating in a research report released on Wednesday, Zacks.com
  reports. According to Zacks, Travere Therapeutics Inc. is a biopharmaceutical company.
  It engages to identify, develop and ...


Travere Therapeutics (NASDAQ:TVTX) Downgraded by Zacks Investment Research

---
- Zacks Investment Research lowered shares of Travere Therapeutics (NASDAQ:TVTX) from
  a buy rating to a hold rating in a research note published on Saturday, Zacks.com
  reports. According to Zacks, Travere Therapeutics Inc. is a biopharmaceutical company.
  It engages to identify, develop and ...


Zacks Investment Research Downgrades Travere Therapeutics (NASDAQ:TVTX) to Hold

---
- Zacks Investment Research upgraded shares of Travere Therapeutics (NASDAQ:TVTX)
  from a sell rating to a hold rating in a research report report published on Wednesday,
  Zacks.com reports. According to Zacks, Travere Therapeutics Inc. is a biopharmaceutical
  company. It engages to identify, ...


Travere Therapeutics (NASDAQ:TVTX) Lifted to Hold at Zacks Investment Research

---
- Shares of Travere Therapeutics, Inc. (NASDAQ:RTRX) hit a new 52-week high during
  mid-day trading on Thursday . The company traded as high as $27.76 and last traded
  at $26.88, with a volume of 302358 shares. The stock had previously closed at $27.05.
  A number of equities research analysts recently ...


Travere Therapeutics (NASDAQ:RTRX) Reaches New 52-Week High at $27.76

---
- NEW YORK Thats another no for the Pharma Bro.A federal judge has rejected convicted
  pharmaceutical executives Martin Shkrelis second request to be let out of prison
  early, showing skepticism about his claim in court papers that mental health issues
  have weakened his immune system and made him more ...


'Pharma Bro' Shkreli loses 2nd bid for early prison release

---
- Zacks Investment Research cut shares of Travere Therapeutics (NASDAQ:TVTX) from
  a hold rating to a sell rating in a research note released on Friday, Zacks.com
  reports. According to Zacks, Travere Therapeutics Inc. is a biopharmaceutical company.
  It engages to identify, develop and deliver ...


Travere Therapeutics (NASDAQ:TVTX) Downgraded to "Sell" at Zacks Investment Research

---
- Cubist Systematic Strategies LLC lessened its position in shares of Travere Therapeutics,
  Inc. (NASDAQ:RTRX) by 36.2% in the third quarter, according to the company in its
  most recent Form 13F filing with the SEC. The fund owned 31,516 shares of the biopharmaceutical
  companys stock after ...


Cubist Systematic Strategies LLC Trims Position in Travere Therapeutics, Inc. (NASDAQ:RTRX)

---
- Travere Therapeutics, Inc. (NASDAQ:RTRX)s share price hit a new 52-week high during
  mid-day trading on Tuesday . The stock traded as high as $28.06 and last traded
  at $27.04, with a volume of 220708 shares traded. The stock had previously closed
  at $27.45. RTRX has been the subject of several recent...


Travere Therapeutics (NASDAQ:RTRX) Reaches New 1-Year High at $28.06

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Watchers	1,009
52-Wk Low	$7.00
52-Wk High	$26.55

Market Cap	$639.84M
Volume (M)	140,953.00
52-Wk High	$26.55
52-Wk Low	$7.00

Current Price	$8.55
Prev Close	$8.05
Open	$8.05
Dividend Yield	0.00%
50-Day Moving Average	$14.16
Beta	1.07
Avg. Volume	1.04M
PE Ratio	-1.89

52-Week High	$26.55
52-Week Low	$7.00
Market Capitalization	$639.84M
EPS	-$4.51
Price to Book	5.49
Revenue Per Employee	$489,294.37
Enterprise Value/EBITDA	-4.18

RTRX Biotech Retrophin

About

Feed

News

Fundamentals